

Supplementary material to: Yap J, Koh SJQ, Aziz ZA, et al. Transcatheter aortic valve implantation for severe aortic regurgitation with Trilogy system: Initial Southeast Asia experience. Ann Acad Med Singap 2026;OnlineFirst.

Table S1: Baseline characteristics, procedural details and clinical outcomes (n=5).

Baseline characteristics	Patients treated with Trilogy valve (n=5)
Male	3
Age, median (range)	75 (49-83)
Ethnicity	
Chinese	4
Malay	1
BMI, median (range)	24.2 (20.7-31.4)
Smoker	0
Diabetes	0
Hypertension	4
Hyperlipidaemia	2
Previous stroke	1
Chronic kidney disease	
Stage 1	1
Stage 2	2
Stage 3a	1
Stage 3b	1
Peripheral arterial disease	0
Obstructive airway disease (asthma and/or COPD)	1
Previous coronary artery disease	1
Previous congestive heart failure	3
NYHA	
I	2
II	3
Underlying rhythm	
Sinus	2
RBBB	1
LBBB	1
Atrial fibrillation	1
STS score (%), median (range)	1.30 (0.60-5.5)
EUROSCORE II (%), median (range)	2.16 (1.01-7.45)
Transthoracic echocardiogram	
Left ventricle ejection fraction <50%	2
Left ventricle end systolic diameter >50mm	1
Mitral regurgitation (at least moderate)	2
Tricuspid regurgitation (at least moderate)	1
Computed tomography measurements	

Aortic valve calcium score, median (range)	0 (0-75)
LVOT diameter (mm), median (range)	23.4 (21-24.6)
Annular perimeter (mm), median (range)	77 (75-84)
Sinotubular junction diameter (mm), median (range)	35 (30-43)
Ascending aorta diameter (mm), median (range)	34 (31-38)
Oversizing percentage (%), median (range)	11 (6.06 – 18)
Procedural details	
Valve size	
S	2
M	3
Procedure time (minutes), median (range)	85 (30-135)
In-hospital VARC 3 clinical end-points	
Procedural success	5
Mortality	0
Myocardial infarction	0
Neurologic events	0
VARC type 2-4 bleeding	0
Vascular complications	0
Cardiac structural complications	0
Other procedural or valve-related complications	0
New conduction disturbances	
New LBBB	1
CHB requiring device	3
Acute kidney injury	0
Median length of stay (days), median (range)	6 (3-13)
3-month VARC 3 clinical end-points	
Mortality	0
Myocardial infarction	0
Neurologic events	0
VARC type 2-4 bleeding	0
Vascular complications	0
Cardiac structural complications	0
Other procedural or valve-related complications	0
Re-hospitalisation	0
NYHA	
I	4
II	1

Bioprosthetic valve dysfunction	
Structural valve deterioration	0
Residual $\geq$ moderate AR	0
Non-structural valve deterioration	0
Thrombosis	0
Endocarditis	0

BMI: body mass index, CHB: complete heart block, COPD: chronic obstructive pulmonary disease, LBBB: left bundle branch block, LVOT: left ventricular outflow tract, NYHA: New York Heart Association RBBB: right bundle branch block, STS: Society of Thoracic Surgeon's VARC: Valve Academic Research Consortium